Penumbra Secures FDA Clearance for THUNDERBOLT with Modulated Aspiration for Stroke Treatment
PEN•Penumbra obtained FDA clearance for its THUNDERBOLT computer assisted vacuum thrombectomy platform, introducing modulated aspiration to address acute ischemic stroke. As the only CAVT device approved for stroke in the U.S., THUNDERBOLT combines the Penumbra ENGINE with RED series catheters to enable faster, more complete clot removal.
1. FDA Clearance for THUNDERBOLT
Penumbra has received FDA clearance to market its THUNDERBOLT CAVT platform for acute ischemic stroke, marking the first computer assisted vacuum thrombectomy device approved in the U.S. specifically for modulated aspiration clot removal.
2. Innovative Modulated Aspiration Technology
THUNDERBOLT integrates the Penumbra ENGINE to deliver controlled, variable suction that detects, fatigues, and fully ingests clots with minimal catheter manipulation, enhancing safety and efficacy when used with RED 62, 68, or 72 catheters.
3. Market Implications and Adoption
As the sole approved CAVT device for stroke, THUNDERBOLT strengthens Penumbra's neurovascular portfolio and could drive procedure volumes globally; commercial launch timing, hospital adoption rates and reimbursement will shape its revenue impact.
